Paradigm Shift in Cellular Therapies for Autoimmune Diseases

Quell Therapeutics Limited, a UK-based innovative biotech company, has commenced a Phase 1/2 clinical trial (CHILL study, NCT07473154) of QEL-005, its first-in-class chimeric antigen receptor T-regulatory cell (CAR-Treg) therapy for autoimmune diseases. Unlike conventional treatments for autoimmune diseases that suppress the entire immune system, increasing susceptibility to infections, this approach aims for precise local immune modulation. This shift from an immunosuppression-centered paradigm towards personalized precision modulation is garnering significant attention in the industry. Notably, Quell Therapeutics has strategically shifted its focus from its initial lead pipeline, a therapy for organ transplant rejection, to the autoimmune disease area, recognizing its greater commercial potential.

New Horizon in the Treatment of Rare and Refractory Diseases

This clinical trial will involve patients with diffuse cutaneous Systemic Sclerosis (dcSSc), a severe autoimmune disease, and refractory Rheumatoid Arthritis (RA), which does not respond to existing standard treatments. Both diseases cause irreversible tissue damage due to chronic inflammation, but there is a lack of safe and effective disease-modifying drugs, resulting in significant unmet medical needs. The market for Systemic Sclerosis treatments is projected to grow from approximately USD $1.5 billion in 2026 to over USD $4 billion by 2035, while the Rheumatoid Arthritis market is already a large market, exceeding USD $38 billion in 2026. If QEL-005 demonstrates disease activity reduction and safety in this trial, it could secure a unique position in this large market for difficult-to-treat diseases.

Unique Mechanism of Action: From Suppression to Harmony

QEL-005 is a cell therapy in which regulatory T cells, isolated from the patient's blood through leukapheresis, are genetically engineered to target the CD19 protein on the surface of B cells. Unlike existing CD19-targeted CAR-T therapies that kill target cells, QEL-005 recognizes and activates CD19 B cells, then exerts bystander suppression, calming surrounding immune cells. Through Quell Therapeutics' proprietary Phenotype Locked™ technology, the Treg cells are designed to maintain stability and prevent them from differentiating into pro-inflammatory T cells even in an inflammatory environment. This cell survival and functional maintenance is a key factor not only for therapeutic efficacy but also for preventing unnecessary systemic side effects.

Long-Term Safety and Regulatory Approval: A Milestone

Following the approval of the clinical trial application (CTA) by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in March 2026, this trial will be expanded into a multinational trial in Spain and Germany. To assess the potential long-term effects of genetically modified cells in the body, as well as potential risks such as carcinogenicity, a one-year primary observation period will be followed by a total of 15 years of long-term follow-up. This rigorous safety verification process will serve as an important standard guideline for regulatory agencies in the future for the approval of next-generation cell therapies. Investors will be able to assess the company's technology based on the initial clinical safety and biomarker data expected to be released in Q1 2027.